Intest Res.  2021 Oct;19(4):478-481. 10.5217/ir.2021.00121.

Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model

• Park J
• Kim DH
• Kim S
• Ma HW
• Park IS
• Son M
• Kim JH
• Shin Y
• Kim SW
• Cheon JH

• KMID: 2521612
• DOI: http://doi.org/10.5217/ir.2021.00121

Figure

• 

  Fig. 1. Escherichia coli Nissle 1917 (EcN) ameliorated dextran sulfate sodium (DSS)-induced colitis. At days 0, 2, and 5, 8-week-old male C57BL/6 mice were administered 1×108 EcN bacteria or phosphate buffered saline daily by gavage (P.O.). 2.5% DSS was added to the drinking water from day 0 and continued for 6 days. Body weight was recorded throughout the 8 days. (A) All mice were euthanized on day 8 of the study and colon length (B), periodic acid-Schiff staining (×100) (C), histomorphological scores (D), and goblet cell score (E) were analyzed. Data are expressed as the mean±standard error of the mean (n=4). Analyses were performed using Mann-Whitney test. aP<0.05, bP<0.01. Veh, phosphate buffered saline-treated vehicle.

• 

  Fig. 2. Anti-inflammatory effects of Escherichia coli Nissle 1917 (EcN) regarding to the inflammatory response associated with T lymphocyte. Splenocytes were isolated from 8-week-old and analyzed T lymphocytes by flow cytometric analysis. Treg differentiation (A), Th1 differentiation (B), and Th17 differentiation (C) in spleens of mice treated with dextran sulfate sodium (DSS) and with or without EcN. Data are expressed as the mean±standard error of the mean (n=4). Analyses were performed using Mann-Whitney test. Veh, phosphate buffered saline-treated vehicle. Foxp3, forkhead box P3; GATA3, GATA binding protein 3; Rorγt, retinoic-acid-receptor-related orphan nuclear receptor gamma.

Reference

1. Scaldaferri F, Gerardi V, Mangiola F, et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J Gastroenterol. 2016; 22:5505–5511.

2. Shafiee NH, Manaf ZA, Mokhtar NM, Raja Ali RA. Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? Intest Res. 2021; 19:171–185.

3. Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res. 2020; 18:151–167.

4. Schultz M, Strauch UG, Linde HJ, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol. 2004; 11:372–378.

5. Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, et al. The Administration of Escherichia coli Nissle 1917 ameliorates development of DSS-induced colitis in mice. Front Pharmacol. 2018; 9:468.

6. Park IS, Son M, Ma HW, et al. Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice. Intest Res. 2021; 19:349–353.

7. Sassone-Corsi M, Nuccio SP, Liu H, et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature. 2016; 540:280–283.

8. Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res. 2020; 18:249–264.

9. Weise C, Zhu Y, Ernst D, Kühl AA, Worm M. Oral administration of Escherichia coli Nissle 1917 prevents allergen-induced dermatitis in mice. Exp Dermatol. 2011; 20:805–809.

10. Kim SH, Lim YJ. The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment. Intest Res. 2021; May. 21. [Epub]. https://doi.org/10.5217/ir.2021.00034.